Pharmaceutical

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.

Jun 20, 2024 - 04:00
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical f...

Next Article

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

STAT+: U.K. sequencing study surfaces new findings abou...

Jan 10, 2024

STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma

STAT+: Leaked study results show a CAR-T from J&J provi...

Apr 19, 2023

Researchers try to tease out possible ties between long Covid and menopause

Researchers try to tease out possible ties between long...

Oct 20, 2023